Stephanie Geno - Innovid Corp Chief Officer
| CTVDelisted Stock | USD 3.14 0.00 0.00% |
Insider
Stephanie Geno is Chief Officer of Innovid Corp
| Phone | 212 966 7555 |
| Web | https://www.innovid.com |
Innovid Corp Management Efficiency
The company has Return on Asset of (0.0257) % which means that on every $100 spent on assets, it lost $0.0257. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0702) %, meaning that it generated no profit with money invested by stockholders. Innovid Corp's management efficiency ratios could be used to measure how well Innovid Corp manages its routine affairs as well as how well it operates its assets and liabilities.Innovid Corp has 21.83 M in debt with debt to equity (D/E) ratio of 0.09, which may show that the company is not taking advantage of profits from borrowing. Innovid Corp has a current ratio of 2.64, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Innovid to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kevin Maczka | Belden Inc | N/A | |
| Dr DPHIL | ADC Therapeutics SA | 65 | |
| Leah Tate | Belden Inc | 48 | |
| MS MBA | ADC Therapeutics SA | 52 | |
| Joseph Camardo | ADC Therapeutics SA | 71 | |
| Ashish Chand | Belden Inc | 50 | |
| Stephane Henchoz | ADC Therapeutics SA | N/A | |
| Anshuman Mehrotra | Belden Inc | 53 | |
| Lajuana Johnson | Comtech Telecommunications Corp | N/A | |
| Thomas Rinderknecht | ADC Therapeutics SA | 67 | |
| Colonel Atcheson | Comtech Telecommunications Corp | N/A | |
| Susan Romanus | ADC Therapeutics SA | 59 | |
| Leo Kulmaczewski | Belden Inc | 58 | |
| Michael Mulkerrin | ADC Therapeutics SA | 69 | |
| Mitchell Walorski | CTS Corporation | N/A | |
| Kimberly Pope | ADC Therapeutics SA | 58 | |
| Lisa Skelton | ADC Therapeutics SA | 53 | |
| Thomas White | CTS Corporation | 38 | |
| Ye Li | CTS Corporation | 53 | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
| Peter Greaney | ADC Therapeutics SA | 41 | |
Management Performance
| Return On Equity | -0.0702 | |||
| Return On Asset | -0.0257 |
Innovid Corp Leadership Team
Elected by the shareholders, the Innovid Corp's board of directors comprises two types of representatives: Innovid Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovid. The board's role is to monitor Innovid Corp's management team and ensure that shareholders' interests are well served. Innovid Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovid Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tanya AndreevKaspin, Executive Officer | ||
| Tim Braz, VP Sales | ||
| Stephanie Geno, Chief Officer | ||
| Stephen Cook, General Counsel | ||
| Ken Markus, Chief Officer | ||
| John Williams, Head Relations | ||
| Pr Netter, CEO CoFounder | ||
| Michal Livny, Executive Resources | ||
| Alex Rowe, Senior Sales | ||
| Anthony Callini, Chief Officer | ||
| Dani Cushion, Chief Officer | ||
| David Helmreich, Chief Officer | ||
| Jeff Austin, Senior Operations | ||
| Kenneth Markus, Chief Officer | ||
| Liel Golan, Executive Operations | ||
| Yuval Pemper, Chief Officer | ||
| Sarah Ripmaster, Senior Accounts | ||
| Tal Chalozin, CoFounder CTO | ||
| Arik Shahar, VP Measurement | ||
| Guy Kuperman, Chief Officer |
Innovid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innovid Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0702 | |||
| Return On Asset | -0.0257 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.04) % | |||
| Current Valuation | 450.54 M | |||
| Shares Outstanding | 150.92 M | |||
| Shares Owned By Insiders | 7.27 % | |||
| Shares Owned By Institutions | 55.65 % | |||
| Number Of Shares Shorted | 3.46 M | |||
| Price To Earning | 23.87 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Innovid Stock
If you are still planning to invest in Innovid Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Innovid Corp's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |